Apolipoprotein(a) induces monocyte chemotactic activity in human vascular endothelial cells

Circulation

Volumn 96, Issue 8, 1997, Pages 2514-2519

  Poon, Michael ^a   Zhang, Xiaoxia ^a   Dunsky, Kevin G ^a   Taubman, Mark B ^a   Harpel, Peter C ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Atherosclerosis; Lipoproteins

Indexed keywords

APOLIPOPROTEIN A;

ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; HUMAN; HUMAN CELL; MONOCYTE; NEUTROPHIL CHEMOTAXIS; PRIORITY JOURNAL; VASCULAR ENDOTHELIUM;

EID: 0030868773     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.96.8.2514     Document Type: Article

References (44)

1. Schaefer EJ, Lamon-Fava S, Jenner JL, McNamara JR, Ordovas JM, Davis CE, Abolafia JM, Lippel K, Levy RI. Lipoprotein(a) levels and risk of coronary heart disease in men. JAMA. 1994;271: 999-1003.
2. Bostom AG, Cupples LA, Jenner JL, Ordovas JM, Seman LJ, Wilson PWF, Schaefer EJ, Castelli WP. Elevated plasma lipoprotein(a) and coronary heart disease in men aged 55 years and younger. JAMA. 1996;276:544-548.
3. Jurgens G, Koltringer P. Lipoprotein(a) in ischemic cerebrovascular disease: a new approach to the assessment of risk for stroke. Neurology. 1987;37:513-515.
4. Willeit J, Kiechi S, Santer P, Oberhollenzer F, Egger G, Jarosch E, Mair A. Lipoprotein(a) and asymptomatic carotid artery disease: evidence of a prominent role in the evolution of advanced carotid plaques: the Bruneck study. Stroke. 1995;26:1582-1587.
5. Cushing GL, Gaubatz JW, Nava ML, Burdick BJ, Bocan TMA, Guyton JR, Weilbaecher D, DeBakey ME, Lawrie GM, Morrisett JD. Quantitation and localization of apolipoproteins(a) and B in coronary artery bypass vein grafts resected at re-operation. Arteriosclerosis. 1989;9:593-603.
6. Desmarais RL, Sarembock IJ, Ayers CR, Vernon SM, Powers ER, Gimple LW. Elevated serum lipoprotein(a) is a risk factor for clinical recurrence after coronary balloon angioplasty. Circulation. 1995;91:1403-1409.
7. Fless GM, ZumMallen ME, Scanu AM. Physicochemical properties of apolipoprotein (a) and lipoprotein (a) derived from the dissociation of human plasma lipoprotein (a). J Biol Chem. 1986;261: 8712-8718.
8. Gaubatz JW, Chari MV, Nava ML, Guyton JR, Morrisett JD. Isolation and characterization of the two major apoproteins in human lipoprotein(a). J Lipid Res. 1987;28:69-79.
9. Eaton DL, Fless GM, Kohr WJ, McLean JW, Xu Q, Miller CG, Lawn RM, Scanu AM. Partial amino acid sequence of apolipoprotein (a) shows that it is homologous to plasminogen. Proc Natl Acad Sci USA. 1987;84:3224-3228.
10. McLean JW, Tomlinson JE, Kuang WJ, Eaton DL, Chen EY, Fless GM, Scanu AM, Lawn RM. cDNA sequence of human apolipoprotein(a) is homologous to plasminogen. Nature. 1987;330:132-137.
11. Rath M, Niendorf A, Reblin T, Dietel M, Krebber H-J, Beisiegel U. Detection and quantification of lipoprotein(a) in the arterial wall of 107 coronary bypass patients. Arteriosclerosis. 1989;9:579-592.
12. Niendorf A, Rath M, Wolf K, Peters S, Arps H, Beisiegel U, Dietel M. Morphological detection and quantification of lipoprotein(a) deposition in atheromatous lesions of human aorta and coronary arteries. Virchows Arch. 1990;417:105-111.
13. Pepin JM, O'Neil JA, Hoff HF. Quantification of apo(a) and apoB in human atherosclerotic lesions. J Lipid Res. 1991;32:317-327.
14. Smith EB, Cochran S. Factors influencing the accumulation in fibrous plaques of lipid derived from low density lipoprotein, II: preferential immobilization of lipoprotein (a) (Lp(a)). Atherosclerosis. 1990;84:173-181.
15. Smith EB, Massie IB, Alexander KM. The release of an immobilized lipoprotein fraction from atherosclerotic lesions by incubation with plasmin. Atherosclerosis. 1976;25:71-84.
16. Beisiegel U, Niendorf A, Wolf K, Reblin T, Rath M. Lipoprotein(a) in the arterial wall. Eur Heart J. 1990;2(suppl E):174-183.
17. Harpel PC, Gordon BR, Parker TS. Plasmin catalyzes binding of lipoprotein (a) to immobilized fibrinogen and fibrin. Proc NatlAcad Sci U S A. 1989;86:3847-3851.
18. Harpel PC, Chang VT, Borth W. Homocysteine and other sulfhydryl compounds enhance the binding of lipoprotein(a) to fibrin: a potential biochemical link between thrombosis, atherogenesis and sulfhydryl compound metabolism. Proc Natl Acad Sci USA. 1992; 89:10193-10197.
19. Zioncheck TF, Powell LM, Rice GC, Eaton DL, Lawn RM. Interaction of recombinant apolipoprotein(a) and lipoprotein(a) with macrophages. J Clin Invest. 1991;87:767-771.
20. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature. 1993;362:801-809.
21. Cushing SD, Berliner JA, Valente AJ, Territo MC, Navab M, Parhami F, Gerrity R, Schwartz CJ, Fogelman AM. Minimally modified low density lipoprotein induces monocyte chemotactic protein 1 in human endothelial cells and smooth muscle cells. Proc Natl Acad Sci USA. 1990;87:5134-5138.
22. Jaffe EA, Hoyer LW, Nachman RL. Synthesis of anti-hemophilic factor antigen by cultured human endothelial cells. J Clin Invest. 1974;52:2754-2764.
23. Smith PK, Krohn RI, Hermanson GT, Mallia AK, Gartner FH, Provenzano MD, Fujimoto EK, Goeke NM, Olson BJ, Klenk DC. Measurement of protein using bicinchoninic acid. Anal Biochem. 1985;150:76-85.
24. Marcovina SM, Hobbs HH, Albers JJ. Relation between number of apolipoprotein(a) kringle 4 repeats and mobility of isoforms in agarose gel: basis for a standardized isoform nomenclature. Clin Chem. 1996;42:436-439.
25. El-Saadani M, Esterbauer H, El-Sayed M, Goher M, Nassar AY, Jurgens G. A spectrophotometric assay for lipid peroxides in serum lipoproteins using a commercially available reagent. J Lipid Res. 1989;30:627-630.
26. Edelstein C, Mandala M, Pfaffinger D, Scanu AM. Determinants of lipoprotein(a) assembly: a study of wild-type and mutant apolipoprotein(a) phenotypes isolated from human and rhesus monkey lipoprotein(a) under mild reductive conditions. Biochemistry. 1995; 34:16483-16492.
27. Borth W, Chang V, Bishop P, Harpel PC. Lipoprotein(a) is a substrate for factor XIIIa and tissue transglutaminase. J Biol Chem. 1991;266:18149-18153.
28. Poon M, Hsu WC, Bogdanov VY, Taubman MB. Secretion of monocyte chemotactic activity by cultured rat aortic smooth muscle cells in response to PDGF is due predominantly to the induction of JE/MCP-1. Am J Pathol. 1996;149:307-317.
29. Poon M, Megyesi J, Green RS, Zhang H, Rollins BJ, Safirstein R, Taubman MB. In vivo and in vitro inhibition of JE gene expression by glucocorticoids. J Biol Chem. 1991;266:22375-22379.
30. Leonard EJ, Yoshimura T. Human monocyte chemoattractant protein (MCP-1). Immunol Today. 1990;11:97-101.
31. Takahashi M, Kitagawa S, Masuyama J-I, Ikeda U, Kasahara T, Takahashi Y-I, Furukawa Y, Kano S, Shimada K. Human monocyte-endothelial cell interaction induces synthesis of granulocyte-macrophage colony-stimulating factor. Circulation. 1995;93:1185-1193.
32. Rollins BJ, Yoshimura T, Leonard EJ, Pober JS. Cytokine-activated human endothelial cells synthesize and secrete a monocyte chemoattractant, MCP-1/JE. Am J Pathol. 1990;136:1229-1233.
33. Lackner C, Boerwinkle E, Leffert CC, Rahmig T, Hobbs HH. Molecular basis of apolipoprotein(a) isoform size heterogeneity as revealed by pulse-field gel electrophoresis. J Clin Invest. 1991;87: 2153-2161.
34. Lackner C, Cohen JC, Hobbs HH. Molecular definition of the extreme size polymorphism in apolipoprotein(a). Hum Mol Genet. 1993;2:933-940.
35. Mancini FP, Mooser V, Guerra R, Hobbs HH. Sequence microheterogeneity in apolipoprotein(a) gene repeats and the relationship to plasma Lp(a) levels. Hum Mol Genet. 1996;4:1535-1542.
36. Marcovina SM, Albers JJ, Gabel B, Koschinsky ML, Gaur VP. Effect of the number of apolipoprotein(a) kringle 4 domains on immunochemical measurements of lipoprotein(a). Clin Chem. 1995;41:246-255.
37. Jurgens G, Taddei-Peters WC, Koltringer P, Petek W, Chen Q, Greilberger J, Macomber PF, Butman BY, Stead AG, Ransom JH. Lipoprotein(a) serum concentration and apolipoprotein(a) phenotype correlate with severity and presence of ischemic cerebrovascular disease. Stroke. 1995;26:1841-1848.
38. Kraft HG, Lingenhel A, Kochl S, Hoppichler F, Kronenberg R, Abe A, Muhlberger V, Schonitzer D, Utermann G. Apolipoprotein(a) kringle IV repeat number predicts risk for coronary heart disease. Arterioscler Thromb Vasc Biol. 1996;16:713-719.
39. Nelken NA, Coughlin SR, Gordon D, Wilcox JN. Monocyte chemoattractant protein-1 in human atheromatous plaques. J Clin Invest. 1991;88:1121-1127.
40. Taubman MB, Rollins BJ, Poon M, Marmur J, Green RS. JE mRNA accumulates rapidly in aortic injury and in platelet-derived growth factor-stimulated vascular smooth muscle cells. Circ Res. 1992;70:314-325.
41. Rovin BH, Dickerson JA, Tan LC, Herbert CA. Activation of nuclear factor-kappa B correlates with MCP-1 expression by human mesangial cells. Kidney Int. 1995;48:1263-1271.
42. Freter RR, Alberta JA, Hwang GY, Wrentmore AL, Stiles CD. Platelet-derived growth factor induction of the immediate-early gene MCP-1 is mediated by NF-kappaB and a 90-kDa phosphoprotein coactivator. J Biol Chem. 1996;271:17417-17424.
43. Ping D, Jones PL, Boss JM. TNF regulates the in vivo occupancy of both distal and proximal regulatory regions of the MCP-1/JE gene. Immunity. 1996;4:455-469.
44. Rajavashisth TB, Andalibi A, Territo MC, Berliner JA, Navab M, Fogelman AM, Lusis AJ. Induction of endothelial cell expression of granulocyte and monocyte/macrophage chemotactic factors by modified low density lipoproteins. Nature. 1990;344:254-257.